Aptose former CMO fully exits stake in Hammi deal
Rhea-AI Filing Summary
Aptose Biosciences Inc. former SVP and Chief Medical Officer Rafael Bejar reported the disposition of his remaining equity stake in connection with a completed acquisition of Aptose by Hammi Pharmaceuticals Co. Inc. A subsidiary of Hammi acquired all outstanding Aptose shares at C$2.41 per share, which the filing converts using an exchange rate of C$1.4 = US$1.00, consistent with a reported common share price of about $1.72 per share.
Bejar disposed of 244 common shares at $1.72 per share and multiple employee and performance stock option awards, each recorded as a Disposition to issuer. After these transactions, the filing shows he holds 0 common shares and no remaining stock options, fully exiting his reported ownership position following the transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
Disposition: 1,578,244 shares
Disposition
7 txns
Insider
Bejar Rafael
Role
Insider
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Employee Stock Option (Right to Buy) | 35,000 | $0.00 | $0.00 |
| Disposition | Employee Stock Option | 200,000 | $0.00 | $0.00 |
| Disposition | Performance Stock Option | 400,000 | $0.00 | $0.00 |
| Disposition | Employee Stock Option (Right to Buy) | 343,000 | $0.00 | $0.00 |
| Disposition | Employee Option Grant | 200,000 | $0.00 | $0.00 |
| Disposition | Employee Stock Option (Right to Buy) | 400,000 | $0.00 | $0.00 |
| Disposition | Common Shares | 244 | $1.72 | $419.68 |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 0 contracts (Direct);
Employee Stock Option — 0 contracts (Direct);
Performance Stock Option — 0 contracts (Direct);
Employee Option Grant — 0 contracts (Direct);
Common Shares — 0 shares (Direct)
Footnotes (4)
- F1. Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share.
- F2. Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
- F3. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.
- F4. Performance stock options subject to specific performance criteria.
Key Figures
Common shares disposed: 244 shares
Common share price: $1.72 per share
Canadian acquisition price: C$2.41 per share
+4 more
7 metrics
Common shares disposed
244 shares
Common Shares at $1.72 per share on 2026-06-30
Common share price
$1.72 per share
Disposition price for 244 Common Shares
Canadian acquisition price
C$2.41 per share
Hammi acquisition price for all outstanding Aptose shares
FX rate used
C$1.4 = US$1.00
Conversion rate for C$2.41 per share to U.S. dollars
Option grant disposed
400,000 option shares
Employee Stock Option, $5.67 exercise price, expires 2030-12-31
Performance options disposed
400,000 option shares
Performance Stock Option, $2.35 exercise price, expires 2031-08-19
Post-transaction holdings
0 shares
Total common shares following all reported transactions
Key Terms
Disposition to issuer, Employee Stock Option, Performance stock options, business arrangement agreement, +1 more
5 terms
Disposition to issuer financial
"each transaction is described with the code D and the phrase "Disposition to issuer""
Employee Stock Option financial
"Security titles include "Employee Stock Option (Right to Buy)" and "Employee Stock Option""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
Performance stock options financial
"A footnote states "Performance stock options subject to specific performance criteria.""
business arrangement agreement financial
"Footnote describes a "business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Inc.""
exercise price financial
"Derivative entries list a "conversion_or_exercise_price" such as 5.6700 and 2.3500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Rafael Bejar report in his Aptose Biosciences (APTOF) Form 4?
Rafael Bejar reported disposing of all his Aptose equity interests. The filing shows sales of 244 common shares and multiple stock option grants as dispositions to the issuer following Hammi Pharmaceuticals’ acquisition of all outstanding Aptose shares.
What happened to Rafael Bejar’s Aptose stock options in this Form 4 filing?
The Form 4 shows multiple employee and performance stock option grants recorded as dispositions to the issuer. Each option grant, tied to underlying common shares at various exercise prices, is reported with zero shares remaining after the transactions, indicating his option positions were eliminated.
What acquisition is referenced in the Aptose Biosciences (APTOF) Form 4 footnotes?
The footnotes describe a business arrangement where a Hammi Pharmaceuticals Co. Inc. subsidiary acquired all outstanding Aptose shares at C$2.41 per share. The deal was approved by the board, shareholders and a court, and underlies the reported dispositions in the Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
